Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

Learn more about:
Related Clinical Trial
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

Official Title

Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy

Brief Summary

      The study is designed as a Phase II, prospective, non randomized, open-label, single arm,
      multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to
      complete surgical resection and progressing to cytotoxic chemotherapy will receive Sorafenib
      plus metronomic chemotherapy as treatment.The aim of this phase II trial is to evaluate the
      clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in
      patients with locally advanced or metastatic ACC who progressed after first or second line
      chemotherapy.
    

Detailed Description

      The study is designed as a Phase II, prospective, non randomized, open-label, single arm,
      multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to
      complete surgical resection.

      STUDY OBJECTIVES

      The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the
      combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or
      metastatic ACC who progressed after first or second line chemotherapy.

      Primary objective

      To assess the clinical benefit as measured by a non progressing rate after 4 months of the
      combination of Sorafenib plus weekly Paclitaxel in patients with locally advanced or
      metastatic ACC who progressed after first or second line chemotherapy.

      Secondary objectives

        -  Assessment of Objective (Complete and Partial) Response Rates

        -  Assessment of Duration of Response

        -  Assessment of Hormonal Response

        -  Assessment of Progression-Free Survival

        -  Assessment of Overall Survival

        -  Assessment of the relationship between specific "biomarkers" and cancer- and
           treatment-related outcomes

        -  Assessment of Quality of Life by EORTC QLQ-C30

        -  Assessment of Toxicity

      ENDPOINTS

      The first disease assessment will be performed after 8-weeks, subsequent assessments will be
      performed every 12 weeks until end of the study.

      Primary endpoint

        -  Progression-Free Survival rate ≥ 40% after 4 months

      Secondary endpoints

        -  Response rate evaluation will be performed according to the RECIST criteria. The same
           methods of measurement and the same technique should be used to characterize each
           identified and reported lesion at baseline and during study.

      TREATMENT SCHEME Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid plus
      intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Disease free survival

Secondary Outcome

 Overall survival

Condition

Adrenocortical Carcinoma

Intervention

Sorafenib

Study Arms / Comparison Groups

 1 arm only
Description:  One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up
Intervention: Sorafenib plus Paclitaxel

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

April 2008

Completion Date

October 2010

Primary Completion Date

October 2009

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of ACC

          -  Locally advanced or metastatic disease not amenable to radical surgery resection

          -  Radiologically monitorable disease

          -  Progressing disease after one or two cytotoxic chemotherapy regimens (including a
             platin-based protocol)

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Subjects with at least one uni-dimensional(for RECIST) or bi-dimensional(for WHO)
             measurable lesion. Lesions must be measured by CT-scan or MRI

          -  Age ≥ 18 years

          -  Adequate bone marrow reserve (neutrophils ≥ 1500/mm³ and platelets ≥ 80.000/mm³)

          -  Hemoglobin > 9.0 g/dl

          -  Total bilirubin < 1.5 times the upper limit of normal

          -  PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically
             anticoagulated with an agent such as coumadin or heparin will be allowed to
             participate provided that no prior evidence of underlying abnormality in these
             parameters exists.]

          -  Serum creatinine < 1.5 x upper limit of normal

          -  Effective contraception in pre-menopausal female and male patients

          -  Patient´s written informed consent

          -  Ability to comply with the protocol procedures

        Exclusion criteria:

          -  History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ
             cervical carcinoma, or other treated malignancies with no evidence of disease for at
             least three years.

          -  History of HIV infection or chronic hepatitis B or C (This criteria should be modified
             to allow Hepatitis B or C in protocols looking at HCC patient population)

          -  Active clinically serious infections (> grade 2 NCI-CTC version 3.0)

          -  Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months
             from definitive therapy, has a negative imaging study within 4 weeks of study entry
             and is clinically stable with respect to the tumor at the time of study entry)

          -  Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          -  History of organ allograft The organ allograft may be allowed as protocol specific

          -  Severe renal (serum creatinine > 2.5 x ULN) or hepatic insufficiency (ALT / - AST >
             2.5 x ULN or ALT/AST >5 x ULN if liver function abnormalities are due to the
             underlying malignancy and/or total serum bilirubin > 2.5 x ULN)

          -  Concomitant Rifampicin

          -  Concomitant St. John's Wort (Hypericum perforatum)

          -  Warfarin is allowed; however, close monitoring of Prothrombin Time (PT) is recommended

          -  Decompensated heart failure (ejection fraction <45%), myocardial infarction or
             revascularization procedure during the last 6 months, unstable angina pectoris,
             uncontrolled cardiac arrhythmia

          -  Hypertension that cannot be controlled by medications (>160/100 mmHg despite optimal
             medical therapy)

          -  Patients with recent or active bleeding diathesis

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within 7 days of the start of treatment.

          -  Both men and women enrolled in this trial must use adequate barrier birth control
             measures during the course of the trial and three months after the completion of trial

          -  Previous treatment with Sorafenib or other anticancer chemotherapy or immunotherapy
             during the study or within 4 weeks of study entry

          -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
             radiotherapy will be allowed).

          -  Major surgery within 4 weeks of start of study

          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study

          -  Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.
             [G-CSF and other hematopoietic growth factors may be used in the management of acute
             toxicity such as febrile neutropenia when clinically indicated or at the discretion of
             the investigator, however they may not be substituted for a required dose reduction.]
             [Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             undertaken within 2 months prior to the study or during the study]

          -  Current treatment with another investigational drug

          -  Any other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

No

Contacts

Alfredo Berruti MD, +390119026, [email protected]

Location Countries

Italy

Location Countries

Italy

Administrative Informations


NCT ID

NCT00786110

Organization ID

EudraCT 2008-000759-91



Study Sponsor

University of Turin, Italy


Study Sponsor

Alfredo Berruti MD, Study Chair, Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Italy


Verification Date

February 2009